优化强大,有效,选择性和透血脑屏障的抑制剂,准EGFRexon20插入突变
Clare Thomson1, Erin Braybrooke1, Nicola Colclough1
1Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Journal of medicinal chemistry
|September 28, 2024
概括
研究人员优化了表皮生长因子受体 (EGFR) Exon20插入 (Ex20Ins) 抑制剂,发现了化合物28. 这种强大而有选择性的分子在模型中表现出有效性,并穿透了血脑屏障.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 表皮生长因子受体 (EGFR) Exon20插入突变是非小细胞肺癌治疗的一个重大挑战.
- 现有的疗法往往缺乏有效性或对这些特定突变具有较差的选择性.
- 开发具有改善药理学特性的向抑制剂,包括穿透血脑屏障至关重要.
研究的目的:
- 通过基于结构的药物设计 (SBDD) 来优化新型表皮生长因子受体 (EGFR) Exon20插入 (Ex20Ins) 抑制剂.
- 确定一种强效的野生型选择性抑制剂,具有有利于中枢神经系统输送的特性.
- 在相关的癌症模型中推进临床前疗效.
主要方法:
- 基于结构的药物设计 (SBDD) 用于代修改化合物.
- 新的双自行车核心的设计是为了增强血脑屏障的透.
- 优化侧重于链接器更换和c-helix交互环的多样化,以提高稳定性.
- 分子质量,H键和极性等分子性质被改进,以获得最佳的大脑暴露.
主要成果:
- 化合物28被确定为一种强效的野生型选择性EGFR Exon20插入抑制剂.
- 化合物28在多个EGFR Ex20Ins异种移植模型中显示出显著的有效性.
- 临床前研究证实了化合物28的血脑屏障透.
- 优化导致光解和代谢稳定性的改善.
结论:
- 化合物28代表了对EGFR Exon20插入突变癌症的有前途的治疗候选者.
- 开发的分子表现出透大脑的有利特性,解决了中枢神经系统瘤学的关键挑战.
- 基于结构的药物设计有效地引导了发现一种强效和选择性的抑制剂,其稳定性和大脑暴露性得到了增强.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
8.5K
相关概念视频
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K